Oncotarget Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations This article dissects Dr. Mikhail V. Blagosklonny’s paradigm-shifting perspective on preemptive combinations for treating... read more June 6, 2024
Oncotarget Combating Doxorubicin-Resistant Acute Myeloid Leukemia In this new study, researchers examined the impact of MIA-602 as monotherapy and in combination... read more May 23, 2024
Oncotarget SARS-CoV-2 Spike Protein Disrupts p53 Tumor Suppressor Pathway In this new study, researchers investigated the interplay between the SARS-CoV-2 spike protein and tumor... read more May 9, 2024
Oncotarget Synergistic Effects of Drug Combinations Targeting AML Cells In this new study, researchers investigated a promising new approach to acute myeloid leukemia (AML)... read more April 11, 2024
Oncotarget Identifying Biomarkers for Predicting Paclitaxel Response In this research perspective, researchers discuss causal and correlative approaches to identify potential biomarkers for... read more March 28, 2024
Oncotarget Antitumor Effects of Sacituzumab Govitecan Plus Platinum-Based Chemotherapy In this study, researchers investigated the antitumor effects of Sacituzumab govitecan in combination with platinum-based... read more March 14, 2024
Oncotarget Raw Areca Nut Betel Quid Consumption and Esophageal Cancer In this new study, researchers provide valuable insights into raw areca nut betel quid consumption... read more February 22, 2024
Oncotarget Oncotarget’s Top 10 Papers Published in 2023 (Crossref Data) Crossref is a non-profit organization that logs and updates citations for scientific publications. Each month,... read more February 15, 2024
Oncotarget Genetic Alterations in Thyroid Cancer: Resistance to BRAFi and Anaplastic Transformation In this new research perspective, researchers discuss the role of genetic alterations in resistance to... read more February 8, 2024
Oncotarget New Drug May Boost Effectiveness of Glioblastoma Treatment In a new study, researchers investigated the activity of gartisertib, a potent ATR inhibitor, alone... read more January 25, 2024